{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:10:21Z","timestamp":1648519821446},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamacardio.2018.2382","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T15:30:56Z","timestamp":1533742256000},"page":"897","source":"Crossref","is-referenced-by-count":1,"title":["Randomized Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific <i>ADCY9<\/i> Genotype\u2014Reply"],"prefix":"10.1001","volume":"3","author":[{"given":"Steven E.","family":"Nissen","sequence":"first","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekumar G.","family":"Pillai","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"hlr180009r1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","article-title":"ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study.","volume":"3","author":"Nissen","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hlr180009r2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"issue":"20","key":"hlr180009r3","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease.","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"hlr180009r4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome.","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"hlr180009r5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/gepi.v33:5","article-title":"Quantifying and correcting for the winner\u2019s curse in genetic association studies.","volume":"33","author":"Xiao","year":"2009","journal-title":"Genet Epidemiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2696437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T16:05:37Z","timestamp":1537373137000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.2382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.2382","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}